文献速递消化系统肿瘤

一线FOLFOXIRI与FOLFOX/FOLFIRI联合贝伐珠单抗的相对剂量强度影响转移性结直肠癌患者预后:TRIBE与TRIBE2研究的汇总分析

The relative dose intensity of first-line FOLFOXIRI and FOLFOX/FOLFIRI both in combination with bevacizumab affects prognosis of metastatic colorectal cancer patients: A pooled analysis of TRIBE and TRIBE2 studies.
PubMed 文献 · Eur J Cancer · 2025-04-26

该汇总分析纳入TRIBE和TRIBE2两项III期研究,比较FOLFOXIRI/贝伐珠单抗与双药(FOLFOX或FOLFIRI)/贝伐珠单抗治疗转移性结直肠癌,评估诱导治疗前8周期相对剂量强度(RDI)<80% vs ≥80%的预后影响。结果显示RDI≥80%与更高的客观缓解率、更长的无进展生存期和总生存期相关;RDI<80%组严重化疗相关不良事件发生率更高。

要点

  • RDI≥80%与更高的ORR(62% vs 53%)、更长的PFS(11.5 vs 10.0个月)和OS(27.9 vs 22.2个月)相关。
  • FOLFOXIRI/贝伐珠单抗RDI<80%组与双药/贝伐珠单抗RDI≥80%组的ORR、PFS和OS无显著差异。
  • RDI<80%组严重化疗相关不良事件发生率更高(72% vs 34%,p<0.001)。

核心结论

  • 维持足够的一线RDI可改善转移性结直肠癌患者的临床结局。
  • 由于低RDI时化疗强化无获益,作者认为针对化疗相关严重不良事件的二级预防可能优于减少单个药物剂量。

研究设计与样本

  • 对III期TRIBE和TRIBE2研究进行汇总分析,比较FOLFOXIRI/贝伐珠单抗与双药(FOLFOX或FOLFIRI)/贝伐珠单抗。
  • 评估诱导治疗前8周期RDI<80% vs ≥80%的预后影响。

主要发现

  • FOLFOXIRI/贝伐珠单抗组282/581(49%)和双药/贝伐珠单抗组404/580(70%)患者接受RDI≥80%。
  • RDI≥80%与更高的ORR(62% vs 53%,OR: 1.44,95%CI: 1.13-1.82;p=0.0026)相关。
  • RDI≥80%与更长的PFS(11.5 vs 10.0个月;HR: 0.80,95%CI: 0.71-0.91;p<0.001)和OS(27.9 vs 22.2个月;HR: 0.75,95%CI: 0.65-0.85;p<0.001)相关。
  • 多变量模型证实上述结果(p<0.001)。
  • FOLFOXIRI/贝伐珠单抗RDI<80%组与双药/贝伐珠单抗RDI≥80%组相比,ORR(58% vs 56%,OR: 1.09,95%CI: 0.81-1.48;p=0.57)、PFS(10.8 vs 10.0个月;HR: 0.96,95%CI: 0.83-1.12;p=0.63)和OS(22.9 vs 24.9个月;HR: 1.07,95%CI: 0.90-1.26;p=0.46)无显著差异。

临床怎么用

  • 作者认为维持足够的一线RDI可改善转移性结直肠癌患者的临床结局。
  • 作者认为低RDI时化疗强化无获益,针对化疗相关严重不良事件的二级预防可能优于减少单个药物剂量。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The relative dose intensity (RDI) of cytotoxic agents affects cancer patients' clinical outcome, especially in the curative setting. Poor data are available in metastatic colorectal cancer (mCRC) and with specific regard to the use of the triplet FOLFOXIRI. METHODS: We performed a pooled analysis of the phase III TRIBE and TRIBE2 studies comparing FOLFOXIRI/bev to doublets (FOLFOX or FOLFIRI)/bev in order to assess the prognostic impact of the RDI (<80 % versus ≥80 %) during the first 8 cycles of induction treatment of both the triplet and the doublet regimens. RESULTS: Overall, 282/581 (49 %) and 404/580 (70 %) of patients treated with FOLFOXIRI/bev and doublets/bev, respectively, received RDI≥ 80 %. Patients receiving RDI≥ 80 % had more favorable clinical condition and tumor-related prognostic features. RDI≥ 80 % was associated with higher ORR (62 % vs 53 %, OR: 1.44, 95 %CI:1.13 - 1.82; p = 0.0026), and longer PFS (11.5 versus 10.0 months; HR: 0.80, 95 %CI: 0.71 - 0.91; p < 0.001) and OS (27.9 versus 22.2 months; HR: 0.75, 95 %CI: 0.65 - 0.85; p < 0.001). These results were confirmed in multivariable models (p < 0.001). Similar ORR (58 % vs 56 %, OR: 1.09, 95 %CI: 0.81-1.48; p = 0.57), PFS (10.8 versus 10.0 months; HR:0.96, 95 %CI: 0.83-1.12; p = 0.63) and OS (22.9 versus 24.9 months; HR:1.07, 95 %CI: 0.90-1.26; p = 0.46) were observed between patients treated with FOLFOXIRI/bev receiving RDI< 80 % and those treated with doublets/bev receiving RDI≥ 80 %. These results were confirmed after stratification for unbalanced baseline characteristics between these subgroups (stratified pORR=0.55; pPFS=0.70; stratified pOS=0.33). As expected, patients in the RDI< 80 % group experienced a higher incidence of severe chemo-related adverse events (72 % vs 34 %, p < 0.001). CONCLUSIONS: Maintaining an adequate RDI in the first-line therapy of mCRC improves patients' clinical outcomes. Since there is no benefit from chemotherapy intensification in the case of low RDI, the secondary prophylaxis of chemotherapy-related severe adverse events might be preferrable rather than individual agents' dose reductions.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Moretto R, Rossini D, Polito MG, et al. The relative dose intensity of first-line FOLFOXIRI and FOLFOX/FOLFIRI both in combination with bevacizumab affects prognosis of metastatic colorectal cancer patients: A pooled analysis of TRIBE and TRIBE2 studies. Eur J Cancer. 2025. PMID: 40306121. doi:10.1016/j.ejca.2025.115470

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。